Literature DB >> 9361155

Methotrexate use in rheumatoid arthritis.

J R O'Dell1.   

Abstract

To overstate the importance of methotrexate in the contemporary management of rheumatoid arthritis would be difficult. It has achieved this distinction because of its efficacy and tolerability. This article reviews the data on the efficacy and toxicity of methotrexate, discusses caveats for clinical use, examines the use of methotrexate in combination therapy, and speculates on the future use of methotrexate in rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9361155     DOI： 10.1016/s0889-857x(05)70360-4

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  11 in total

1.  Low dose methotrexate and bone marrow suppression.

Authors:  Michael Sosin; Sunil Handa
Journal:  BMJ       Date:  2003-02-01

Review 2.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 3.  New therapies for rheumatoid arthritis.

Authors:  F Goldblatt; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

4.  Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria.

Authors:  Tim Niehues; Gerd Horneff; Hartmut Michels; Michaela Sailer Höck; Lothar Schuchmann
Journal:  Rheumatol Int       Date:  2005-02-02       Impact factor: 2.631

Review 5.  Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials.

Authors:  Amy C Cannella; James R O'Dell
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis.

Authors:  Gloris Sánchez; Julio S Castro; Soham Al Snih; Luísa Pérez Blanco; María H Esteva; Ernesto García Macgregor; Marielena González; Ysabel Granados; Francisco Marín; Alexis Rosas; Antonio Tristano; Esther Chirinos; Luís Mundaraín; Gilberto Sanoja; Guisela Zambrano-Marín; Martín A Rodríguez
Journal:  Rheumatol Int       Date:  2006-11-11       Impact factor: 2.631

Review 7.  Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.

Authors:  Roy Fleischmann; Imran Iqbal; Pallavi Nandeshwar; Andres Quiceno
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Recommendations for the use of methotrexate in juvenile idiopathic arthritis.

Authors:  Tim Niehues; Petra Lankisch
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 9.  [Methotrexate in the therapy of juvenile idiopathic arthritis].

Authors:  D Holzinger; M Frosch; D Föll
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

10.  Treatment of experimental adjuvant arthritis with the combination of methotrexate and lyophilized Enterococcus faecium enriched with organic selenium.

Authors:  J Rovenský; K Svík; M Stancíková; R Istok; L Ebringer; M Ferencík
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.